Severe deterioration of newly diagnosed Takayasu arteritis in a patient re-treated with interferon beta-1α for concomitant longstanding multiple sclerosis

References

• Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009;48(8):1008–11.
   PubMed Web of Science ®Google Scholar
• Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002;55(7):481–6.
   PubMed Web of Science ®Google Scholar
• Mason JC. Takayasu arteritis-advances in diagnosis and man-agement. Nat Rev Rheumatol. 2010;6(7):406–15.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359(9313):1221–31.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol. 2003;23(2):133–46.
   PubMed Web of Science ®Google Scholar
• Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda S. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient. J Clin Neurosci. 2007;14(10):997–1000.
   PubMed Web of Science ®Google Scholar
• Crispin JC, Diaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus. 2005;14(6):495–6.
   PubMed Web of Science ®Google Scholar
• Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23(10):677–83.
   Google Scholar
• Biggioggero M, Gabbriellini L, Meroni PL. Type 1 interferon therapy and its role in autoimmunity. Autoimmunity. 2010; 43(3):248–54.
   Google Scholar
• Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther. 2010;12(Suppl 1):S1.
   PubMedGoogle Scholar
• Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12): 975–90.
   PubMed Web of Science ®Google Scholar
• Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol. 2002;71(4):565–81.
   PubMed Web of Science ®Google Scholar
• Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Thl type immunity and is associated with induction of INF-alpha/beta. Proc Natl Acad Sci USA. 2001;98(10):5752–7.
   PubMed Web of Science ®Google Scholar
• Karp CL, Biron CA, Irani DN. Interferon beta in multiple scle-rosis: is IL-12 suppression the key? Immunol Today. 2000; 21(1):24–8.
   Google Scholar
• Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon alpha/beta-mediated inhibition and promo-tion of interferon gamma: Statl resolves a paradox. Nat Immunol. 2000;1(1):70–6.
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB. Type-I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity. 2003;36(8):473–9.
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type-I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307–36.
   PubMed Web of Science ®Google Scholar
• Baccala R, Kono DH, 'Theofilopoulos AN. Interferons as patho-genic effectors in autoimmunity. Immunol Rev. 2005;204:9–26.
   Google Scholar
• Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity. 2003;36(8):511–8.
   PubMed Web of Science ®Google Scholar
• Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood. 2002;99(9):3263–71.
   PubMed Web of Science ®Google Scholar
• Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type-I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161(4):1947–53.
   PubMed Web of Science ®Google Scholar
• Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, et al. Type-I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000;191(10):1777–88.
   Google Scholar
• Biron CA. Interferons alpha and beta as immune regulators-a new look. Immunity. 2001;14(6):661–4.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resis-tance and adaptive immunity. Nat Rev Immunol. 2003;3(2): 133–46.
   PubMed Web of Science ®Google Scholar
• Manack P, Kappler J, Mitchell T. Type I interferons keep acti-vated T cells alive. J Exp Med. 1999;189(3):521–30.
   Google Scholar
• Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993;178(5):1655–63.
   PubMed Web of Science ®Google Scholar
• Sharara Al, Perkins DJ, Misukonis MA, Chan SU, Dominitz JA, Weinberg JB. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relation-ship of induced N052 to the anti-hepatitis C effects of IFN-alpha in vivo. J Exp Med. 1997;186(9):1495–502.
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Ban-chereau J. Plasmacytoid dendritic cells induce plasma cell dif-ferentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225–34.
   Google Scholar
• Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol. 2002;169(8):4279–87.
   PubMed Web of Science ®Google Scholar
• Wessely R. Interference by interferons: Janus faces in vascular proliferative diseases. Cardiovasc Res. 2005;66(3):433–43.
   PubMed Web of Science ®Google Scholar
• Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199(2):173–83.
   Google Scholar
• Seko Y, Minota S, Kawasaki A, Shinkai Y, Maeda K, Yagita H, et al. Perforin-secreting killer cell infiltration and expression of a 65-kd heat-shock protein in aortic tissue of patients with Taka-yasu's arteritis. J Clin Invest. 1994;93(2):750–8.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Bjornsson J, Bartley GB, Goronzy JJ, Weyand CM. Interferon-gamma-producing T cells in giant cell vasculitis rep-resent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol. 1996;148(6):1925–33.
   Google Scholar
• Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003;349(2):160–9.
   PubMed Web of Science ®Google Scholar
• Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 2006;45(5):545–8.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest. 1994;94(3):1134–40.
   Google Scholar
• Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA rep-ertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin Exp Immunol. 2004;138(2):369–74.
   Google Scholar
• Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004;3(1):46–53.
   PubMed Web of Science ®Google Scholar
• Seko Y. Takayasu arteritis: insights into immunopathology. Jpn Heart J. 2000;41(1):15–26.
   PubMedGoogle Scholar
• Chauhan SK, Singh M, Nityanand S. Reactivity of gamma/delta T cells to human 60-kd heat-shock protein and their cytotoxicity to aortic endothelial cells in Takayasu arteritis. Arthritis Rheum. 2007;56(8):2798–802.
   Google Scholar
• Inder SJ, Bobryshev YV, Cherian SM, Wang AY, Lord RS, Masuda K, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg. 2000;8(2):141–8.
   PubMedGoogle Scholar
• Sima D, Thiele B, Turowski A, Wilke K, Hiepe F, Volk D, et al. Anti-endothelial antibodies in Takayasu arteritis. Arthritis Rheum. 1994;37(3):441–3.
   PubMedGoogle Scholar
• Nityanand S, Mishra K, Shrivastava S, Holm G, Lefvert AK. Autoantibodies against cardiolipin and endothelial cells in Takayasu's arteritis: prevalence and isotype distribution. Br J Rheumatol. 1997;36(8):923–4.
   Google Scholar
• Baltazares M, Mendoza F, Dabague J, Reyes PA. Antiaorta antibodies and Takayasu arteritis. Int J. Cardiol. 1998;66\(Suppl 1):5183–7. Discussion S189.
   Google Scholar
• Tripathy NK, Sinha N, Nityanand S. Anti-annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity. Clin Exp Immunol. 2003;134(2):360–4.
   Google Scholar
• Tripathy NK, Sinha N, Nityanand S. Antimonocyte antibodies in Takayasu's arteritis: prevalence of and relation to disease activ-ity. J Rheumatol. 2003;30(9):2023–6.
   Google Scholar
• Chauhan SK, Tripathy NK, Nityanand S. Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Taka-yasu arteritis. Arthritis Rheum. 2006;54(7):2326–33.
   Google Scholar
• Kumar Chauhan S, Kumar Tripathy N, Sinha N, Singh M, Nityanand S. Cellular and humoral immune responses to myco-bacterial heat shock protein-65 and its human homologue in Takayasu's arteritis. Clin Exp Immunol. 2004;138(3):547–53.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Younge BR, Goronzy H. IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23(1):43–9.
   Google Scholar
• Seko Y. Giant cell and Takayasu arteritis. Curr Opin Rheumatol. 2007;19(1):39–43.
   PubMed Web of Science ®Google Scholar